OREANDA-NEWS. Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, will host a breakfast meeting focused on the treatment of acute inner ear tinnitus and AM-101's Phase 3 clinical development program. The event will take place from 8 am to 9:30 am EDT on Tuesday, June 14, 2016, in New York City. The meeting will feature a presentation by Hinrich Staecker, MD, PhD, who serves as a principal investigator in the Company's TACTT2 trial, as well as presentations by members of the Auris Medical leadership team.

Hinrich Staecker, MD, PhD, completed medical school at the Albert Einstein College of Medicine with distinction in Otology Research. After completing his residency in otolaryngology at Montefiore Medical Center, Dr. Staecker went on to a fellowship in Otology and Neurotology at Harvard Medical School's Massachusetts Eye and Ear. He is dual board certified in Otolaryngology and Neurotology by the American Board of Otolaryngology. Currently, Dr. Staecker is the David and Mary Zamierowsky Professor at University of Kansas School of Medicine, a member of the Collegium Oto-Rhino-Laryngologica, a fellow of the Triological Society, and a member of the American Otological Society. 

The AM-101 Phase 3 clinical development program includes the TACTT2 and TACTT3 trials. The TACTT2 trial has enrolled more than 330 patients and is being conducted primarily in North America under a Special Protocol Assessment (SPA) with the US Food and Drug Administration. Top-line results from this trial are expected in August 2016. The TACTT3 trial is being conducted in Europe, and enrollment of approximately 630 patients (300 in the acute stage and 330 in the post-acute stage) is expected to be completed by the end of June 2016. Top-line results from this trial are expected in the fourth quarter of 2016.

Auris Medical is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology. The Company is currently focusing on the development of treatments for acute inner ear tinnitus (AM-101) and for acute inner ear hearing loss (AM-111) by way of intratympanic injection with biocompatible gel formulations. In addition, Auris Medical is pursuing early-stage research and development projects. The Company was founded in 2003 and is headquartered in Zug, Switzerland. The shares of the parent company Auris Medical Holding AG trade on the NASDAQ Global Market under the symbol "EARS."

Auris Medical is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology. The Company is currently focusing on the development of treatments for acute inner ear tinnitus (AM-101) and for acute inner ear hearing loss (AM-111) by way of intratympanic injection with biocompatible gel formulations. In addition, Auris Medical is pursuing early-stage research and development projects. The Company was founded in 2003 and is headquartered in Zug, Switzerland. The shares of the parent company Auris Medical Holding AG trade on the NASDAQ Global Market under the symbol "EARS."